Trusted Partner for Your Cell & Gene Therapy Commercialization
MedTherapy Biotech is a Boston based global Cancer Cell & Gene Therapy Company founded in 2018 by experts from Harvard and former Novartis executives as an end-to-end, integrated CAR-T Cell CDMO, with commercial scale GMP manufacturing facility in New Delhi, India and technology development site at Boston, USA.
Our Services
Manufacturing CAR-T cell gene therapy for cancer patients encompasses three disparate components: running clinical trials to develop these therapies, manufacturing CAR-T cell gene therapies, and manufacturing the most critical raw materials called virus vectors.
MedTherapy Biotech is one of the very few companies in the world that can undertake all these three critical activities in-house. This assures our success and accomplishes our mission to make these therapies more affordable and accessible.
MedTherapy Biotech offers end-to-end services for its partners and collaborators to translate their Cell & Gene Therapy products from early stage through late stage through commercialization and beyond.
Our Technology
Car-T cell therapy Manufacturing
Manufacturing CAR-T cell gene therapies is very complex. And time consuming – almost 4-6 weeks for a patient. This leads to both- delays in manufacturing, and, exorbitant costs. MedTherapy has developed innovative technologies to speed up the process. Our technologies together with our state of art global facilities and expertise allows to dramatically reduce costs and time for manufacturing these therapies.
